Contract analysis
Clause-by-clause risk read on any document of the firm. Pick a contract, or open any document from a matter.
Contract analysis / email-cross-to-team-appeals-prep-20240215.eml
email-cross-to-team-appeals-prep-20240215.eml
High · 1
Medium · 0
Standard · 0
1. PPC's **4.5% royalty rate** sits squarely within the arm's-length range (IQR 3.1%–6.8%,
1. PPC's **4.5% royalty rate** sits squarely within the arm's-length range (IQR 3.1%–6.8%, median 4.4%) based on 14 comparable uncontrolled transactions. The IRS's 11.0% rate is based on cherry-picked, non-comparable agreements.
2. PBI's **cost-sharing percentages (38.2%–42.7%)** accurately reflect reasonably anticipa
2. PBI's **cost-sharing percentages (38.2%–42.7%)** accurately reflect reasonably anticipated benefits. The IRS's proposed increases of 8–12 percentage points are unsupported by the actual revenue data and projections.
3. The **$312M PCT payment** falls within the $278M–$361M arm's-length range using a prope
3. The **$312M PCT payment** falls within the $278M–$361M arm's-length range using a properly risk-adjusted WACC of 9.8%. The IRS's 7.2% discount rate understates the risk inherent in pharmaceutical IP development. 4. **PBI has robust economic substance** — this is not a brass-plate entity. 185 employees, 42 board meetings, €47.2M in regulatory submissions, independent pricing across 68 markets. The DEMPE analysis cl
5. PPC maintained **contemporaneous documentation** for all four years, prepared by Crestf
High
⚑ Penalty / liquidated damages
5. PPC maintained **contemporaneous documentation** for all four years, prepared by Crestfield & Associates. The § 6662(e) penalty is unsupportable — both on reasonable cause and documentation grounds. --- **SETTLEMENT POSTURE** As established in our December 10, 2023 memo, our target resolution is **10–15% of the $380.4M proposed adjustment**, with a **hard ceiling of 20%**. We should not initiate settlement discuss